Published in

Future Medicine, Epigenomics, 3(11), p. 337-347, 2019

DOI: 10.2217/epi-2018-0094

Elsevier, European Urology Supplements, 11(18), p. e3562, 2019

DOI: 10.1016/s1569-9056(19)34698-6

Links

Tools

Export citation

Search in Google Scholar

A two-gene methylation signature for the diagnosis of bladder cancer in urine

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Aim: To analyze the potential of 14 cancer-associated genes, including six miRNAs, for bladder cancer (BC) diagnosis in urine. Patients & methods: DNA methylation levels of 14 genes were analyzed in urine of 72 BC patients and 75 healthy controls using quantitative methylation-specific PCR. Multivariate logistic regression analysis was used to determine an optimal marker panel. Results: Ten genes were significantly hypermethylated in BC patients. The GHSR/MAL combination showed the best diagnostic performance, reaching a sensitivity of 92% (95% CI: 86–99) and a specificity of 85% (95% CI: 76–94). Conclusion: We identified a novel two-gene panel with a high diagnostic accuracy for BC that can be applied in a noninvasive, urine-based test.